Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting



 Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American
                   Academy of Ophthalmology Annual Meeting

-- OMS302 also to be Featured in "Cutting Edge" Symposium --

PR Newswire

SEATTLE, Nov. 12, 2013

SEATTLE, Nov. 12, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today
announced that it will present data from its Phase 3 clinical program for
OMS302 at the American Academy of Ophthalmology (AAO) Annual Meeting, which
will take place from November 16 through November 19 in New Orleans,
Louisiana. The presentation, "Two Phase 3 Trials of OMS302 in Irrigation
Solution for Maintenance of Mydriasis in Intraocular Lens Replacement (ILR)"
includes key analyses from the Phase 3 program for OMS302. These analyses are
included in both the US and European marketing applications for OMS302. Steve
Whitaker, M.D., Omeros' vice president of clinical development and chief
medical officer, will present the data on November 17 in Hall C.

OMS302 was also selected to be included in the symposium at AAO entitled
"Cataract Surgery: The Cutting Edge," which features novel technologies for
cataract surgery for presentation and discussion by an expert international
panel. The symposium is scheduled to begin at 12:15 pm on November 17 in The
Great Hall.

About Omeros' OMS302 Program
OMS302 is Omeros' product being developed for use during intraocular lens
replacement (ILR), including cataract surgery and refractive lens exchange.
OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent
phenylephrine and the anti-inflammatory agent ketorolac. Omeros' NDA for
OMS302 has been accepted for filing by the FDA and its MAA for OMS302 has been
validated by the EMA.

ILR involves replacement of the original lens of the eye with an artificial
intraocular lens. These procedures are typically performed to replace a lens
opacified by a cataract or to correct a refractive error of the lens (i.e.,
refractive lens exchange). OMS302 is added to standard irrigation solution
used in ILR and delivered within the eye to maintain intraoperative mydriasis
(pupil dilation), to reduce surgically induced miosis (pupil constriction),
and to reduce postoperative pain and irritation. Maintenance of mydriasis is
critical to the safety and surgical ease of the procedure. Intraoperative
pupil constriction increases the risk of injury to intraocular structures and
can substantially prolong surgical time.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering,
developing and commercializing small-molecule and protein therapeutics
targeting inflammation, coagulopathies and disorders of the central nervous
system. Derived from its proprietary PharmacoSurgery^® platform, the Company's
lead drug product, OMS302 for lens replacement surgery, is currently under
review for marketing approval by both the US Food and Drug Administration and
the European Medicines Agency with commercial launch planned for 2014. Omeros'
five other clinical programs are focused on schizophrenia, Huntington's
disease and cognitive impairment; addictive and compulsive disorders;
complement-related diseases; and preventing problems associated with surgical
procedures. Omeros also has a proprietary GPCR platform, which is making
available an unprecedented number of new GPCR drug targets and corresponding
compounds to the pharmaceutical industry for drug development.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, which are subject to the "safe harbor" created by those
sections for such statements. All statements other than statements of
historical fact are forward-looking statements, which are often indicated by
terms such as "anticipate," "believe," "could," "estimate," "expect," "goal,"
"intend," "may," "plan," "potential," "predict," "project," "should," "will,"
"would" and similar expressions. Forward-looking statements are based on
management's beliefs and assumptions and on information available to
management only as of the date of this press release. Omeros' actual results
could differ materially from those anticipated in these forward-looking
statements for many reasons, including, without limitation, risks associated
with Omeros' unproven preclinical and clinical development activities,
regulatory oversight, product commercialization, intellectual property claims
and the risks, uncertainties and other factors described under the heading
"Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on November 7, 2013. Given these risks,
uncertainties and other factors, you should not place undue reliance on these
forward-looking statements, and the Company assumes no obligation to update
these forward-looking statements, even if new information becomes available in
the future.

SOURCE Omeros Corporation

Contact: Jennifer Cook Williams, Cook Williams Communications, Inc., Investor
and Media Relations, +1-360-668-3701, jennifer@cwcomm.org
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement